Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEMAND III: Drisapersen in Duchenne Muscular Dystrophy
NCT01254019Phase 3Completed
- Sponsor
- GSK
- Start
- Dec 2010
- Primary completion
- Jun 2013
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 20
01
Overview
A Phase 3 trial of drisapersen in Duchenne muscular dystrophy (DMD), sponsored by GSK. Started Dec 2010; status: completed.
02
Drugs
drisapersen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT01254019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01254019.